JLE

Médecine thérapeutique

MENU

Traitement biologique de la maladie de Still de l’adulte Volume 25, numéro 2, Mars-Avril 2019

  • [1] Franchini S., Dagna L., Salvo F. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. Arthritis Rheum. 2010;62:2530-2535.
  • [2] Gerfaud-Valentin M., Maucort-Boulch D., Hot A. Adult-onset Still disease: manifestations, treatments, outcome, and prognostic factors in 57 patients. Medicine. 2014;93:91-99.
  • [3] Mitrovic S, Fautrel B. De nouveaux marqueurs pour la maladie de Still de l’adulte. Rev Rhum. 2018;85:121-131.
  • [4] Gerfaud-Valentin M., Jamilloux Y., Iwaz J. Adult onset Still's disease. Autoimmun Rev. 2014;13:1149-1159.
  • [5] Kim Y.J., Koo B.S., Kim Y.G., Lee C.K., Yoo B. Clinical features and prognosis in 82 patients with adult-onset Still's disease. Clin Exp Rheumatol. 2014;32:28-33.
  • [6] Wahb M., Rachidi W., Nassar K., Janani S., Mkinsi O. Maladie de still de l’adulte : mise au point thérapeutique. Rev Mar Rhum. 2015;32:32-38.
  • [7] Jamilloux Y., Gerfaud-Valentin M., Henry T. Treatement of adult onset Still's disease. Ther Clin Risk Manag. 2015;11:33-43.
  • [8] Fautrel B., Borget C., Rozenberg S. Cortisosteroid sparing effet of low dose methotrexate in adult Still's disease. J Rheumatol. 1999;26:373-378.
  • [9] Vignes S., Wechsler B., Amoura Z. Intravenous immunoglobulin in adult Still's disease refractory to non steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 1998;16:295-298. 3
  • [10] Kraetsch H.G., Antoni J.C., Kalden J.R., Manger B. Successful treatment of a small cohort of patients with adult onset Still's disease with infliximab: first experiences. Ann Rheum Dis. 2001;60:55-57.
  • [11] Fautrel B., Sibilia J., Mariette X. Tumour necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. Ann Rheum Dis. 2005;64:262-266.
  • [12] Husni M.E., Maier A.L., Mease P.J. Etanercept in the treatment of adult patients with Still's disease. Arthritis Rheum. 2002;46:1171-1176.
  • [13] Serratrice J., Granel B., DisdierP, Weiller P.J., Dussol B. Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult's Still disease. Am J Med. 2003;115:589-590.
  • [14] Kaneko K., Kaburaki M., Muraoka S. Exacerbation of adult-onset Still's disease, possibly related to elevation of serum tumor necrosis factor-alpha after etanercept administration. Int J Rheum Dis. 2010;13:67-69.
  • [15] Agarwal S., Moodley J., AjaniGoel G., Theil K.S., Mahmood S.S., Lang R.S. A rare trigger for macrophage activation syndrome. Rheumatol Int. 2011;31:405-407.
  • [16] Fitzgerald A.A., Leclercq S.A., Yan A., Homik J.E., Dinarello C.A. Rapid responses to anakinra in patients with refractory adult onset Still's disease. Arthritis Rheum. 2005;52:1794-1803. 6
  • [17] Lequerré T., Quartier P., Rosellini D. Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann Rheum Dis. 2008;67:302-308. 3
  • [18] Giampietro C., Ridene M., Lequerre T. Anakinra in adult-onset Still's disease: long-term treatment in patients resistant to conventional therapy. Arthritis Care Res. 2013;65:822-826.
  • [19] Lyseng-Williamson K.A. Anakinra in Still's disease: a profile of its use. Drug Therap Perspect. 2018;34:543-553.
  • [20] Pouchot J., Arlet J.B. Biological treatment in adult-onset Still's disease. Best Pract Reas Clin Rheum. 2012;26:477-487.
  • [21] Petryna O., Cush J.J., Efthimiou P. IL-1 traprilonacept in refractory adult onset Still's disease. Ann Rheumatic Dis. 2012;71:2056-2057.
  • [22] Elkayam O., Jiries N., Dranitzki Z. Tocilizumab in adult-onset Still's disease: the Israeli experience. J Rheumatol. 2014;41:244-247.
  • [23] Cipriani P., Ruscitti P., Carubbi F. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol. 2013;33:49-55.
  • [24] Puechal X., De Bandt M., Berthelot J.M. Tocilizumab in refractory adult Still's disease. Arthritis Care Res. 2011;63:155-159.
  • [25] Ortiz-Sanjuán F., Blanco R., Calvo-Rio V. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol. 2014;66:1659-1665.
  • [26] De Bandt M., Saint-Marcoux B. Tocilizumab for multi refractory adult-onset Still's disease. Ann Rheum Dis. 2009;68:153-154.
  • [27] Kobayashi M., Takahashi Y., Yamashita H. Benefit and a possible risk of tocilizumab therapy for adult-onset Still's disease accompanied by macrophage-activation syndrome. Mod Rheumatol. 2011;21:92-96.